The Supreme Court agreed to consider a dispute between Novartis and Amgen that could determine how soon cheaper, copycat versions of biotechnology drugs can be sold to consumers.
WSJ.com: US Business, Wall Street Journal: Business
Fri, 01/13/2017 - 1:52pm
The Supreme Court agreed to consider a dispute between Novartis and Amgen that could determine how soon cheaper, copycat versions of biotechnology drugs can be sold to consumers.